Immunome Inc.

8-K · imnm-20260609.htm iXBRL

0001472012 2026-06-09 2026-06-09

  
 UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
  
  
 FORM 8-K
  
  
 CURRENT REPORT
 Pursuant to Section 13 or 15(d)
 of the Securities Exchange Act of 1934
  
 Date of Report (Date of earliest event reported):
 June 9, 2026
  
  
 Immunome, Inc.
 (Exact name of registrant as specified in its charter)
  
  

 Delaware

 001-39580

 77-0694340

 (state or other jurisdiction
 of incorporation)

 (Commission
 File Number)

 (I.R.S. Employer
 Identification No.)

  

 18702 N. Creek Parkway, Suite 100
 Bothell , WA

 98011

 (Address of principal executive offices)

 (Zip Code)

  
 Registrant’s telephone number, including area code: ( 425 ) 939-7410
  
 N/A
 (Former name or former address, if changed since last report.)
  
  
 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
  

 ☐

 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 ☐

 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 ☐

 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 ☐

 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  
 Securities registered pursuant to Section 12(b) of the Act:
  

 Title of each class

 Trading Symbol

 Name of each exchange
 on which registered

 Common Stock, $0.0001 par value per share

 IMNM

 The Nasdaq  Capital Market

  
 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
  
 Emerging growth company ☐
  
 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
  

  

 Item 5.07 Submission of Matters to a Vote of Security Holders.
 Immunome, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders on June 9, 2026 (the “Annual Meeting”). As of April 16, 2026, the record date for the Annual Meeting, 113,249,519 shares of common stock were outstanding and entitled to vote at the Annual Meeting. The following tables set forth the final results of the voting for the matters voted upon at the Annual Meeting. These matters are described in more detail in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 24, 2026 (the “Proxy Statement”).
 Proposal 1: Election of Directors
 The Company’s stockholders elected the three persons listed below as Class III directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders, and until their successors are duly elected and qualified, or until their earlier death, resignation or removal. The final voting results are as follows:
  

  

  

Votes For

  

Votes Withheld

  

 Broker
Non-Votes

 James Boylan

  

 70,209,570

  

 22,171,996

  

 11,768,578

 Sandra Swain, M.D.

  

 92,157,301

  

 224,265

  

 11,768,578

 Philip Wagenheim

  

 92,162,632

  

 218,934

  

 11,768,578

 Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm
 The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 by the Audit Committee of the Company’s Board of Directors. The final voting results are as follows:
  

Votes For

  

Votes Against

  

 Abstentions

 Broker Non-Votes

 104,100,900

  

 27,134

  

 22,110

 -

 Proposal 3: Advisory Vote on Executive Compensation
 The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as described in the Proxy Statement. The final voting results are as follows:
  

Votes For

  

Votes Against

  

 Abstentions

 Broker Non-Votes

 90,908,436

  

 1,442,116

  

 31,014

 11,768,578

 Proposal 4: Advisory Vote on the Frequency of Solicitation of Advisory Stockholder Approval of Executive Compensation
 The Company’s stockholders indicated, on an advisory basis, their preference for the frequency of stockholder advisory votes on the compensation of the Company’s named executive officers. The final voting results are as follows:
  

 1 Year

 2 Years

 3 Years

 Abstentions

 Broker Non-Votes

 91,949,591

 368,407

 41,534

 22,034

 11,768,578

  
 Consistent with these results, the Company determined that future stockholder advisory votes on named executive officer compensation will be held every year until the next required advisory vote on the frequency of stockholder advisory votes on named executive officer compensation.
  

  

  

 SIGNATURES
 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
  

 Date: June 12, 2026

 Immunome, Inc.

  

  

  

 By:

 /s/ Max Rosett

  

 Name:

 Max Rosett

  

 Title:

 Chief Financial Officer